Jasper Therapeutics appoints Edwin Tucker as CMO
- Jasper Therapeutics (NASDAQ:JSPR) notifies the appointment of Dr. Edwin J. Tucker as Jasper’s Chief Medical Officer.
- Concurrently, Jasper also announced the appointment of Dr. Daniel Adelman, who had been serving as Jasper’s Acting Chief Medical Officer, to its Scientific Advisory Board and to the position of Senior Clinical Advisor.
- The accomplished Biotech and large pharma executive to lead Briquilimab Clinical Development Programs.
- Dr. Tucker, most recently served as Chief Medical Officer at Goldfinch Bio, where he led clinical development and helped build the regulatory, medical affairs and clinical operations functions.
- Previously Dr. Adelman served as Vice President of Clinical Operations and Biometrics at Pharmacyclics, and as a Clinical Scientist at Genentech.
- In connection with the appointment of Dr. Tucker, Jasper granted him an option to purchase 400K shares of voting common stock, with exercise price of the option of $1.62.
- The option will vest over four years, with 25% of the total number of shares vesting on June 12, 2024 and 1/48th of the total number of shares subject to the Option vesting monthly thereafter.